SECAUCUS, N.J., June 27, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report.
This year's report provides information on the company's corporate responsibility strategy and environmental, social, and governance (ESG) priorities, which align with The Quest Way, the company's approach to achieving its goals. The Quest Way is comprised of the company's Purpose, strategy and culture.
"The theme of this year's report, Care at Our Core, builds on our Purpose of working together to create a healthier world, one life at time," said Jim Davis, Chairman, CEO and President.
"The Quest Way guides our corporate responsibility strategy and progress toward our environmental, social, and governance priorities and goals. This report shares some of our contributions from 2023 and demonstrates how we are continuing to improve our processes and capabilities surrounding this work. I am proud of our critical role in healthcare and how our workforce is the engine that expands access and advances innovative contributions."
The report details the initiatives supporting the company's four corporate responsibility strategic pillars:
The report features key impact areas and highlights from 2023, including:
"In 2023, we made good progress across all of our pillars, especially in the areas of employee and community engagement," said Sam Samad, Executive Vice President and Chief Financial Officer, who leads the team guiding the company's ESG efforts. "Our efforts to create a healthier world require collaboration with our employees, customers, partners and communities where we operate, and those efforts are driving tangible results."
Click here to view the report on the Quest Diagnostics corporate website.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Last Trade: | US$170.68 |
Daily Change: | 1.06 0.62 |
Daily Volume: | 349,730 |
Market Cap: | US$19.050B |
April 22, 2025 April 09, 2025 April 02, 2025 March 18, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load